These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 10306394)
1. The Maximum Allowable Cost program--some marketing consequences. Gosselin RA Med Mark Media; 1978 Feb; 13(2):19-20, 22, 24 passim. PubMed ID: 10306394 [No Abstract] [Full Text] [Related]
2. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy. Paul SH Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270 [No Abstract] [Full Text] [Related]
3. Use of generics will mean cost savings. Nelson G Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132 [No Abstract] [Full Text] [Related]
4. Maximum allowable cost for drugs. Hosp Formul; 1975 Mar; 10(3):116, 119-20. PubMed ID: 10237830 [No Abstract] [Full Text] [Related]
5. Maximum allowable cost: can the government control drug costs? Smith MI; Wertheimer AI J Health Polit Policy Law; 1979; 4(2):155-75. PubMed ID: 385712 [TBL] [Abstract][Full Text] [Related]
6. How to pay less for prescription drugs. Consum Rep; 1975 Jan; 40(1):48-53. PubMed ID: 1244036 [No Abstract] [Full Text] [Related]
7. Generic vs. brand name drugs--quality, not cost, is key issue. Stetler CJ Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133 [No Abstract] [Full Text] [Related]
8. Letter: Opposition to MAC. Dougherty RL Am Fam Physician; 1975 Jun; 11(6):31-4. PubMed ID: 1130257 [No Abstract] [Full Text] [Related]
10. MAC--a cutting tool for federal reimbursements on prescription drugs? Hirsh HL J Leg Med (N Y); 1976 Feb; 4(2):31-3. PubMed ID: 1082483 [No Abstract] [Full Text] [Related]
11. [The distribution and consumption of subsidized medicine. A preliminary account to illustrate the consequences of reduction of the subsidies for medicine]. Hilden J Ugeskr Laeger; 1974 Nov; 136(45):2539-45. PubMed ID: 4417068 [No Abstract] [Full Text] [Related]
12. Pharmacy: how cost-effective are generics? Wolfe H Hospitals; 1973 May; 47(9):100-8. PubMed ID: 4702078 [No Abstract] [Full Text] [Related]
13. Generic Drugs. Med Lett Drugs Ther; 2002 Oct; 44(1141):89-90. PubMed ID: 12405134 [No Abstract] [Full Text] [Related]
14. PBS charges. Harvey K Med J Aust; 1991 Mar; 154(5):364-5. PubMed ID: 2017069 [No Abstract] [Full Text] [Related]
15. Drug substitution--boon to consumers versus legal trap for the professional. Brennan BJ J Leg Med (N Y); 1976 Mar; 4(3):20-5. PubMed ID: 1083405 [No Abstract] [Full Text] [Related]
16. How to live with Section 223 (routine service cost limits). Stango M Hosp Financ Manage; 1977 Apr; 31(4):48-51. PubMed ID: 10305259 [No Abstract] [Full Text] [Related]
17. The economics of drug prescribing in Ireland. O'Hanrahan M; O'Malley K Ir Med J; 1981 Oct; 74(10):309-10, 312. PubMed ID: 7309452 [No Abstract] [Full Text] [Related]
18. Prescription discounts for health centers. Cauchi R; Hanson K NCSL Legisbrief; 2002 Jan; 10(5):1-2. PubMed ID: 11852940 [No Abstract] [Full Text] [Related]
19. Excess profits in the drug industry and their effect on consumer expenditures. Doherty N Inquiry; 1973 Sep; 10(3):19-30. PubMed ID: 4269726 [No Abstract] [Full Text] [Related]
20. Price controls and global pharmaceutical progress. Scherer FM Health Aff (Millwood); 2009; 28(1):w161-4. PubMed ID: 19088103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]